Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapa-Stress: Dapagliflozin and Stress in T1D
NCT04234867Phase 1Terminated
- Sponsor
- Kinderkrankenhaus Auf der Bult
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dapagliflozin in type 1 diabetes mellitus (T1D), sponsored by Kinderkrankenhaus Auf der Bult. Primary endpoint: Time to development of Diabetic Ketoacidosis at 12 hours. Started May 2022; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04234867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234867.